- Citations, last 5 years
- 13.8k
- Works, last 5 years
- 2 014
- h-index
- 580
- Scientists listed
- 0
- Grants since 2016
- 630
Grants received
2025–2028 · grant · MRP
Immunotherapeutic Targeting of SLC39A9 in CDKN2A-Low Melanoma
Katherine Aird · The Wistar Institute · funded by Congressionally Directed Medical Research Programs
2025–2027 · award
Next-Generation Models of AM to Map Therapeutic Vulnerabilities
Jessie Villanueva · The Wistar Institute · funded by Melanoma Research Alliance
2025–2028 · grant · MRP
Immunotherapeutic Targeting of SLC39A9 in CDKN2A-Low Melanoma
Raquel Buj Gomez · The Wistar Institute · funded by Congressionally Directed Medical Research Programs
2025–2029 · research · R01
MEPCS (Multi-epitope protease cleavage sites) vaccine for protecting against SIV rectal transmission
Qingsheng Li · The Wistar Institute · funded by National Institutes of Health
2025–2030 · research · R01
Cell intrinsic and extrinsic effects of zinc metabolism in therapy resistant melanoma
Katherine Marie Aird · The Wistar Institute · funded by National Institutes of Health
2025–2030 · cooperative agreement · UM1
Individualized HIV Curative Combination Strategy against Persistent HIV on ART
Luis J Montaner · The Wistar Institute · funded by National Institutes of Health
2024–2029 · research · R01
Developing potent HIV-specific CAR T cells through optimizing antigen sensitivity
Daniel Thomas Claiborne · The Wistar Institute · funded by National Institutes of Health
2024–2028 · grant · OCRP
Targeting Resident Macrophages to Treat Metastatic Ovarian Cancer
Nan Zhang · The Wistar Institute · funded by Congressionally Directed Medical Research Programs
2024–2025 · research · R01
The genetics of tumor suppression by p53 - Diversity Supplement
Maureen E. Murphy · The Wistar Institute · funded by National Institutes of Health
2024–2029 · research · R01
Remodeling of the host epigenome during EBV infection
Italo Tempera · The Wistar Institute · funded by National Institutes of Health
2024–2029 · research · R37
Characterizing the sources, mechanisms, and translational relevance of microbial TMAO in driving anti-tumor immunity in pancreatic cancer.
Rahul Suresh Shinde · The Wistar Institute · funded by National Institutes of Health
2024–2026 · award
Developing S6K2-selective degraders: A novel approach for acral melanoma
Jessie Villanueva · The Wistar Institute · funded by Melanoma Research Alliance
2024–2029 · research · R35
Regulation of gene expression by alternative polyadenylation
Bin Tian · The Wistar Institute · funded by National Institutes of Health
2024–2027 · grant · Standard Grant
Tri-State Expansion, Curriculum Evolution, and Equity during BioTechnician Training (Tri ExCEEd BTT)
Kristy Mcguire · The Wistar Institute · funded by National Science Foundation
2024–2029 · research · R01
Transcriptional Reprogramming in Melanoma Plasticity
Chengyu Liang · The Wistar Institute · funded by National Institutes of Health
2024–2029 · research · R01
Parkin tumor suppression
Dario C Altieri · The Wistar Institute · funded by National Institutes of Health
2024–2029 · research · R01
R-loop functions in neuronal gene expression and genome organization
Kavitha Sarma · The Wistar Institute · funded by National Institutes of Health
2024–2028 · research · R01
Computational methods for discovery of disease-modulating microbial genes
Noam Auslander · The Wistar Institute · funded by National Institutes of Health
2024–2029 · research · R35
Regulation of gene expression by alternative polyadenylation
Bin Tian · The Wistar Institute · funded by National Institutes of Health
2024–2029 · research · R37
Characterizing the sources, mechanisms, and translational relevance of microbial TMAO in driving anti-tumor immunity in pancreatic cancer.
Rahul Suresh Shinde · The Wistar Institute · funded by National Institutes of Health
2024–2029 · research · R35
Regulation of gene expression by alternative polyadenylation
Bin Tian · The Wistar Institute · funded by National Institutes of Health
2024–2029 · research · R01
Developing potent HIV-specific CAR T cells through optimizing antigen sensitivity
Daniel Thomas Claiborne · The Wistar Institute · funded by National Institutes of Health
2024–2028 · research · R01
Computational methods for discovery of disease-modulating microbial genes
Noam Auslander · The Wistar Institute · funded by National Institutes of Health
2024–2026 · research · R01
Transcriptional Reprogramming in Melanoma Plasticity
Chengyu Liang · The Wistar Institute · funded by National Institutes of Health
2024–2029 · research · R01
Parkin tumor suppression
Dario C Altieri · The Wistar Institute · funded by National Institutes of Health
2024–2029 · research · R01
Remodeling of the host epigenome during EBV infection
Italo Tempera · The Wistar Institute · funded by National Institutes of Health
2024–2028 · research · R00
Reprogramming T cell function with multiplexed genome engineering to develop next-generation immunotherapy
Xiaoyu Zhou · The Wistar Institute · funded by National Institutes of Health
2024–2029 · research · R01
R-loop functions in neuronal gene expression and genome organization
Kavitha Sarma · The Wistar Institute · funded by National Institutes of Health
2023–2028 · research · R01
Metabolic and molecular regulation of myeloid cell functions in brain cancer
Filippo Veglia · The Wistar Institute · funded by National Institutes of Health
2023–2028 · research · R01
Interrogating Type I Interferon signaling in breast cancer brain metastasis
Qing Chen · The Wistar Institute · funded by National Institutes of Health
2023–2027 · grant · Continuing Grant
REU Site: Molecular Basis of Cellular Phenotypes (MBCP) at The Wistar Institute
David Zuzga · The Wistar Institute · funded by National Science Foundation
2023–2026 · award
Vaccine-tunable TME-restricted CAR T therapy for long-term melanoma control
Leyuan Ma · The Wistar Institute · funded by Melanoma Research Alliance
2023–2026 · grant · MSRP
Epstein-Barr Virus-Driven B-Cell Inflammation and CNS Trafficking in MS
Paul Lieberman · The Wistar Institute · funded by Congressionally Directed Medical Research Programs
2023–2027 · grant · OCRP
Epigenetic Reprogramming to Target Senescent Ovarian Cancer Cells and Overcome Therapeutic Resistance
Katherine Aird · The Wistar Institute · funded by Congressionally Directed Medical Research Programs
2023–2025 · research · R01
Functional Analysis of p53 Polymorphic Variants - Diversity Supplement
Maureen E. Murphy · The Wistar Institute · funded by National Institutes of Health
2023–2026 · grant · MRP
Developing Rational Approaches for Acral Melanoma
Jessie Villanueva · The Wistar Institute · funded by Congressionally Directed Medical Research Programs
2023–2028 · research · R01
The genetics of tumor suppression by p53
Maureen E. Murphy · The Wistar Institute · funded by National Institutes of Health
2023–2028 · program · P01
Targeting the Epigenetic and Metabolic Control of EBV-Epithelial Cancers
Paul M. Lieberman · The Wistar Institute · funded by National Institutes of Health
2023–2028 · program · P01
Targeting the Epigenetic and Metabolic Control of EBV-Epithelial Cancers
Paul M. Lieberman · The Wistar Institute · funded by National Institutes of Health
2023–2028 · research · R01
EBNA1 Inhibitor for Treatment of EBV-positive DLBCL
Paul M. Lieberman · The Wistar Institute · funded by National Institutes of Health